Cameco vs. Oklo: The Nuclear Market’s Defining Tug-of-War
Cameco brings cash flow and contracts, Oklo brings vision and volatility — the nuclear trade now hinges on which future investors believe in.
The nuclear renaissance is no longer a whisper—it’s a full-throated roar in 2025, and two names keep dominating the conversation: Oklo (NYSE: OKLO), the Silicon Valley darling promising pocket-sized reactors for the AI age, and Cameco (NYSE: CCJ), the Canadian uranium gorilla that’s been feeding reactors for decades. Both stocks have been on an absolute tear, but after Oklo’s 50%+ haircut from its September peak and Cameco quietly stacking new contracts, investors are asking the same uncomfortable question: which one is the better value before the next leg higher—or lower?
Let’s start with the spectacle. Oklo, the Sam Altman-backed small modular reactor (SMR) pioneer, closed December 4, 2025, at $110.25 after a 14% intraday surge, giving it a market cap just north of $16.2 billion. That’s right—a company with exactly zero dollars in trailing revenue is now worth more than many established industrial giants. To put that in perspective, Oklo’s valuation is roughly 40% of Cameco’s $40.5 billion market cap, despite Cameco posting C$2.62 billion in revenue over the past twelve months and swinging to a healthy C$391 million in net income.
Cameco shares, up a more measured 89% year-to-date through December 4, trade at 103 times trailing earnings and roughly 75 times 2026 consensus estimates (some desks still quote closer to the 64 times forward multiple cited in recent research). Expensive? Without question. Justifiable? Increasingly so, when you consider the structural uranium deficit the world is sleepwalking into.
Here’s the cold reality: global uranium demand is on track to rise 50% by 2030 according to the International Energy Agency, while supply remains choked by years of under-investment and geopolitical risk. Cameco controls roughly 18% of world production through its tier-one assets like McArthur River and Cigar Lake, and its 49% stake in Westinghouse adds a lucrative nuclear-services kicker. More importantly, 70% of its expected output through 2028 is already locked in under long-term contracts—an annuity-like profile that Oklo investors can only dream about for now.
Oklo, for all its brilliance, is still a pre-commercial story. The company’s Aurora micro-reactor won’t flip the switch on its first grid-connected unit until late 2027 at the earliest, with meaningful revenue unlikely before 2028. Analysts currently project somewhere between $5 million and $18 million in 2028 sales—optimistic scenarios push toward $1 billion by 2030 if everything goes perfectly. That’s a lot of “ifs” for a $16 billion price tag.
Don’t get me wrong: the technology is genuinely exciting. Safer, factory-built, walk-away-safe reactors sized perfectly for hyperscale data centers are exactly what the AI power crunch ordered. Partnerships are stacking up, the ADVANCE Act is greasing regulatory wheels, and Oklo ended the third quarter with $1.2 billion in cash after a well-timed capital raise. But excitement isn’t the same as value, and right now the market is paying an astronomical premium for a vision that still needs multiple regulatory sign-offs and flawless execution.
Cameco, by contrast, is selling a commodity the world literally cannot live without if it wants 24/7 carbon-free power. Uranium spot prices have pulled back 10% in recent weeks, yet the long-term supply-demand imbalance remains brutal. Kazatomprom is capping production, Russian export risks linger, and Western utilities are scrambling to secure non-Russian pounds. Every pound Cameco pulls out of the ground today is essentially pre-sold at prices far higher than the cost of production.
So which is the better buy on December 4, 2025? If you’re hunting for a five-year compounder backed by cash flow, contracts, and the most concentrated high-grade uranium reserves on the planet, Cameco wins in a landslide. If you’re willing to embrace full speculative mode and believe Oklo executes its 2027–2030 roadmap without a single major hiccup, the SMR story still has multibagger potential—but you’re paying a valuation that already assumes perfection.
For most investors, the math is simple: one stock has earnings, dividends (albeit tiny), and a moat measured in hundreds of millions of pounds of uranium. The other has PowerPoint decks and a dream. Dreams can come true—just ask anyone who bought Oklo at $8 eighteen months ago—but at today’s prices, Cameco is the grown-up in the room offering real value in a sector that’s only getting hotter.
Sources: Company filings (Q3 2025 10-Q/10-K equivalents), Yahoo Finance closing prices December 4 2025, Bloomberg consensus estimates, International Energy Agency World Energy Outlook 2025, World Nuclear Association uranium supply reports, UxC quarterly uranium market outlook (Q4 2025), and NRC public licensing timelines for Oklo Aurora combined license application.